Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.59 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | CFD | P00746 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | ELANE | P08246 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | VEGFA | P15692 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14710190 | 0.86 | LMNA (0.46) | CYP4F2CYP4A11LMNACYP3A4MAPT | |
| SCHEMBL1995396 | 0.86 | CYP4F2 (0.69) | CYP4F2CYP4A11LMNACYP3A4MAPT | |
| SCHEMBL3453107 | 0.86 | LMNA (0.50) | CYP4F2CYP4A11LMNACYP3A4MAPT | |
| SCHEMBL5534885 | 0.84 | LMNA (0.45) | CYP4F2CYP4A11LMNACYP3A4MAPT | |
| SCHEMBL27574759 | 0.81 | MEN1 (0.44) | CYP4F2CYP4A11MEN1KMT2AVEGFA | |
| SCHEMBL22305552 | 0.81 | CYP4F2 (0.39) | CYP4F2CYP4A11VEGFA | |
| SCHEMBL3434711 | 0.80 | CYP4F2 (0.39) | CYP4F2CYP4A11KMT2AACHEHSD17B10 | |
| SCHEMBL27484827 | 0.80 | CYP4F2 (0.42) | CYP4F2CYP4A11LMNAKDM4EKMT2A | |
| SCHEMBL13141031 | 0.78 | LMNA (0.53) | CYP4F2CYP4A11LMNACYP3A4MAPT | |
| SCHEMBL10765006 | 0.78 | KMT2A (0.44) | CYP4F2CYP4A11LMNACYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583856-B2 | Inhibitors of protein kinase A | BLUEPRINT MEDICINES CORPORATION (US) | 2026-03-24 | — | — | US | disclosed |
| EP-3917527-B1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-113645971-B | Compounds and uses thereof | 福宏治疗公司 | 2024-10-18 | — | — | CN | disclosed |
| US-20240132490-A1 | INHIBITORS OF PROTEIN KINASE A | BLUEPRINT MEDICINES CORPORATION (US) | 2024-04-25 | — | — | US | disclosed |
| CN-117751115-A | Compounds, compositions, and methods of treating cancer | 热点治疗公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2023151642-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE , LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023151640-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE , LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023151641-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE , LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
| US-20230079819-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-03-16 | — | — | US | disclosed |
| WO-2022165402-A1 | INHIBITORS OF PROTEIN KINASE A | BLUEPRINT MEDICINES CORPORATION (US) | 2022-08-04 | — | — | WO | disclosed |
| US-20140170111-A1 | FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohmn Corp. (US) | 2014-06-19 | — | — | US | disclosed |
| CN-102596957-A | Substituted pyrazolo [1,5-a ] pyrimidine compounds as TRK kinase inhibitors | ARRAY BIOPHARMA INC | 2012-07-18 | — | — | CN | disclosed |
| EP-2451812-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-05-03 | — | — | US | disclosed |
| WO-2012050848-A1 | FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | SCHERING CORPORATION (US) | 2012-04-19 | — | — | WO | disclosed |
| WO-2012041014-A1 | TETRACYCLIC INDOLE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012041227-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS FOR TREATING HEPATITIS C VIRAL INFECTION | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012040923-A1 | TETRACYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012040924-A1 | FUSED TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2011006074-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079819-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | CYP4F2 2084/4885CYP4A11 2926/4885LMNA 225/4885 |
| US-12583856-B2 | Inhibitors of protein kinase A | CSNK1A1, CSNK1A1L, CSNK1G1 | CYP4F2 2402/4885CYP4A11 1142/4885LMNA 1662/4885 |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | FRK, TXK, TNNI3K | CYP4F2 3312/4885CYP4A11 3386/4885LMNA 2799/4885 |
| US-20140170111-A1 | FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | HAVCR2, ZC3HAV1, ZC3HAV1L | CYP4F2 117/4885CYP4A11 110/4885LMNA 1820/4885 |
| US-20240132490-A1 | INHIBITORS OF PROTEIN KINASE A | PRKCA, MAP3K6, MAP3K1 | CYP4F2 3320/4885CYP4A11 2681/4885LMNA 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.